Drug design targeting active posttranslational modification protein isoforms.

Area of Science:

• Drug discovery and development
• Medicinal chemistry
• Molecular biology

Background:

• Modern drug design faces challenges in exploring the vast chemical space to find effective molecules.
• The limited and discrete nature of biological space creates a bottleneck in identifying drug candidates with optimal properties.
• Post-translational modifications (PTMs) create diverse protein isoforms that represent an underexplored area for drug targeting.

Purpose of the Study:

• Introduce a novel drug design paradigm, Post-translational Modification Inspired Drug Design (PTMI-DD).
• Expand the intersection of chemical and biological space for drug discovery.
• Highlight the therapeutic potential of targeting PTM protein isoforms.

Main Methods:

• Leveraging PTM protein isoform target space to inspire drug design strategies.
• Rationalizing the importance and roles of PTM protein isoforms in disease and biological functions.
• Proposing specific PTMI-DD approaches: covalent inhibitors, targeting unique isoform binding sites, modulating PTM-related protein-protein interactions, and utilizing ubiquitination for targeted protein degradation.

Main Results:

• PTMI-DD significantly expands the accessible biological space for drug discovery.
• Targeting PTM protein isoforms increases compound tractability and relevance to biological functions.
• This approach enhances opportunities for precision medicine through isoform-specific targeting.

Conclusions:

• PTMI-DD offers a promising new direction for overcoming drug discovery bottlenecks.
• Targeting PTM protein isoforms can lead to more effective and selective therapeutics.
• This strategy holds potential for advancing personalized medicine and treating complex diseases.